Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes

NCT07399678 is registered in ClinicalTrials.gov with Alveus Therapeutics, Inc. as lead sponsor.

NCT NCT07399678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07399678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes
Lead sponsor
Alveus Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 29, 2025
Completion date
September 30, 2027
Enrollment
180 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obese adults, overweight or obese, type 2 diabetes